The use of mesenchymal stem cells in the treatment of osteogenesis imperfecta: An integrative and qualitative review of literature
DOI:
https://doi.org/10.33448/rsd-v14i3.48420Keywords:
Mesenchymal stem cells; Osteogenesis imperfecta; Treatment.Abstract
Osteogenesis Imperfecta (OI) is a hereditary bone disease that affects children, resulting in extreme bone weakness leading to musculoskeletal deformities and fractures. OI is caused by mutations in the genes that code to produce collagen in bones, a substance essential for the formation and strength of bones. Based on this, the objective of this review is to investigate the role of mesenchymal stem cells in the treatment of osteogenesis imperfecta as well as to investigate innovative therapies in the treatment of the disease. This study is a qualitative and integrative review of the literature carried out through an active search in the Medical Literature Analysis and Retrieve System Online (medline) database, in accordance with the precepts established by the Standards qualitative research guideline. For Reporting Qualitative Research (SRQR). Articles published in full without language restrictions were selected for analysis and inclusion based on the controlled DeCS/MESH descriptors: mesenchymal stem cells and osteogenesis imperfecta through the combination of words with the Boolean descriptors AND and OR in the information sources. It was observed in the study that treatment with mesenchymal stem cells brought hope to patients with osteogenesis imperfecta since pre-clinical studies in animal models and clinical studies demonstrated a reduction in the occurrence of fractures and an improvement in bone density with this type of therapy.
References
Anima. (2014). Manual de revisão bibliográfica sistemática integrativa: uma pesquisa baseada em evidências. Grupo Anima. https://biblioteca.cofen.gov.br/wp-content/uploads/2019/06/manual_revisao_bibliografica-sistematica-integrativa.pdf.
Arthur, A., & Gronthos, S. (2020). Clinical application of bone marrow mesenchymal stem/stromal cells to repair skeletal tissue. Em International Journal of Molecular Sciences, 21(24), 1–27.
Botor, M., Fus-Kujawa, A., Uroczynska, M., Stepien, K. L., Galicka, A., Gawron, K., & Sieron, A. L. (2021). Osteogenesis imperfecta: Current and prospective therapies. Em Biomolecules, 11(10).
Chevrel, G., Cimaz, R. (2006). Osteogenesis Imperfecta: New Treatment Options. Current Rheumatology Reports 8(6) 473-479.
Crossetti, MGM (2012). Revisão integrada da investigação em enfermaria com o rigor científico exigido. Rev. Gaúcha Enferm. 33(2): 8-9.
Dinulescu, A., Păsărică, A. S., Carp, M., Dușcă, A., Dijmărescu, I., Pavelescu, M. L., Păcurar, D., & Ulici, A. (2024). New Perspectives of Therapies in Osteogenesis Imperfecta—A Literature Review. Em Journal of Clinical Medicine (Vol. 13, Número 4). Multidisciplinary Digital Publishing Institute (MDPI).
Götherström, C., David, A. L., Walther-Jallow, L., Åström, E., & Westgren, M. (2021). Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta. Clinical Obstetrics & Gynecology, 64(4), 898–903.
Götherström, C., & Walther-Jallow, L. (2020). Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta. Em Current Osteoporosis Reports 18(4), 337–343. Springer.
Götherström, C., Westgren, M., Shaw, S. W. S., Åström, E., Biswas, A., Byers, P. H., Mattar, C. N. Z., Graham, G. E., Taslimi, J., Ewald, U., Fisk, N. M., Yeoh, A. E. J., Lin, J.-L., Cheng, P.-J., Choolani, M., Le Blanc, K., & Chan, J. K. Y. (2014). Pre- and Postnatal Transplantation of Fetal Mesenchymal Stem Cells in Osteogenesis Imperfecta: A Two-Center Experience. Stem Cells Translational Medicine, 3(2), 255–264.
Infante, A., Cabodevilla, L., Gener, B., & Rodríguez, C. I. (2022). Circulating TGF-β Pathway in Osteogenesis Imperfecta Pediatric Patients Subjected to MSCs-Based Cell Therapy. Frontiers in Cell and Developmental Biology, 10.
Infante, A., Gener, B., Vázquez, M., Olivares, N., Arrieta, A., Grau, G., Llano, I., Madero, L., Bueno, A. M., Sagastizabal, B., Gerovska, D., Araúzo‐Bravo, M. J., Astigarraga, I., & Rodríguez, C. I. (2021). Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro‐osteogenic paracrine response: TERCELOI clinical trial. Clinical and Translational Medicine, 11(1).
Jones, G. N., Moschidou, D., Abdulrazzak, H., Kalirai, B. S., Vanleene, M., Osatis, S., Shefelbine, S. J., Horwood, N. J., Marenzana, M., De Coppi, P., Bassett, J. H. D., Williams, G. R., Fisk, N. M., & Guillot, P. V. (2014). Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta. Stem Cells and Development, 23(3), 262–276.
Kindler, V., Suva, D., Soulas, C., & Chapuis, B. (2006). Hematopoietic stem cells and mesenchymal stem cells as tools for present and future cellular therapies. Swiss Medical Weekly, 333–337.
Lang, E., & Semon, J. A. (2023). Mesenchymal stem cells in the treatment of osteogenesis imperfecta. Em Cell Regeneration, 12(1). Springer.
Le Blanc, K., Götherström, C., Ringdén, O., Hassan, M., McMahon, R., Horwitz, E., Anneren, G., Axelsson, O., Nunn, J., Ewald, U., Nordén-Lindeberg, S., Jansson, M., Dalton, A., Åström, E., & Westgren, M. (2005). Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation, 79(11), 1607–1614.
Li, F., Armstrong, G. B., Tombran-Tink, J., & Niyibizi, C. (2016). Pigment Epithelium Derived Factor upregulates expression of Vascular Endothelial Growth Factor by human Mesenchymal Stem cells: Possible role in PEDF regulated matrix mineralization HHS Public Access. Biochem Biophys Res Commun, 478(3), 1106–1110.
Liu, Y., Wu, J., Zhu, Y., & Han, J. (2014). Therapeutic application of mesenchymal stem cells in bone and joint diseases. Em Clinical and Experimental Medicine, 14(1), 13–24).
Pereira, A.S et al. (2018). Metodologia da pesquisa científica. [e-book gratuito]. Editora. UAB/NTE/UFSM.
Undale, A., Westendorf, J., Yaszemski, M., Khosla, S. (2009). Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clinic Proceedings. 84(10) 893-902.
Ramesh, S., Daniel, D., Götherström, C., & Madhuri, V. (2021). Trophic effects of multiple administration of mesenchymal stem cells in children with osteogenesis imperfecta. Clinical and Translational Medicine, 11(4).
Satija, N. K., Singh, V. K., Verma, Y. K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R. P., & Gurudutta, G. U. (2009). Mesenchymal stem cell-based therapy: A new paradigm in regenerative medicine. Journal of Cellular and Molecular Medicine, 13(11–12), 4385–4402.
Sinder, B. P., Novak, S., Wee, N. K. Y., Basile, M., Maye, P., Matthews, B. G., & Kalajzic, I. (2020). Engraftment of skeletal progenitor cells by bone-directed transplantation improves osteogenesis imperfecta murine bone phenotype. Stem Cells, 38(4), 530–541.
Snyder, H. (2019). Revisão de literatura como metodologia de pesquisa: visão geral e diretrizes. Jornal de pesquisa empresarial, 104, 333-339.
Westgren, M., & Götherström, C. (2015). Stem cell transplantation before birth - a realistic option for treatment of osteogenesis imperfecta? Prenatal Diagnosis, 35(9), 827–832.
Wong, R. S. Y. (2011). Mesenchymal stem cells: Angels or demons? Em Journal of Biomedicine and Biotechnology (Vol. 2011).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kamily Iracema Coimbra Lima; Isac da Silva Monteiro; Klever Luiz Ribeiro; Messias de Lima Azevedo; Mônica Regina Hosannah da Silva e Silva; Kadmiel Cândido Chagas
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
